2seventy bio to lay off 40% of workforce

Adds details on job cuts, CEO transition in paragraphs 2-4

Sept 12 (Reuters) - 2seventy bio TSVT.O said on Tuesday it plans to lay off about 40% of its workforce to lower costs and focus on the biotech firm's cancer cell therapy Abecma.

The company will save about $130 million in 2024-25 as it eliminates 176 roles.

2seventy bio said it expects a decline in Abecma sales in the third quarter and U.S. revenue for the therapy in 2023 could be lower than the $470-$570 million range it previously projected.

The company added that CEO Nick Leschly will step down and transition to the role of chairman.

(Reporting by Pratik Jain in Bengaluru; Editing by Shounak Dasgupta)


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


More Related Articles

Info icon

This data feed is not available at this time.

Sign up for Smart Investing to get the latest news, strategies and tips to help you invest smarter.